564443-27-2

Basic information

• Product Name: 6-(trifluoromethyl)imidazo[2,1-b]thiazole-5-carbaldehyde
• Synonyms: 6-(trifluoromethyl)imidazo[2,1-b]thiazole-5-carbaldehyde;6-(trifluoromethyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde
• CAS NO: 564443-27-2
• Molecular Formula: C₇H₃F₃N₂OS
• Molecular Weight: 220.1717296
• Mol File: 564443-27-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.69g/cm³
• Refractive Index: 1.619
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 6-(trifluoromethyl)imidazo[2,1-b]thiazole-5-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(trifluoromethyl)imidazo[2,1-b]thiazole-5-carbaldehyde(564443-27-2)
• EPA Substance Registry System: 6-(trifluoromethyl)imidazo[2,1-b]thiazole-5-carbaldehyde(564443-27-2)

Safety Data

• Hazardous Substances Data: 564443-27-2(Hazardous Substances Data)

Usage

General Description

6-(trifluoromethyl)imidazo[2,1-b]thiazole-5-carbaldehyde is a chemical compound with the molecular formula C8H4F3N3OS. It is a synthetic organic compound that contains a trifluoromethyl group and an imidazole ring. 6-(trifluoromethyl)imidazo[2,1-b]thiazole-5-carbaldehyde has functional groups that make it useful in a variety of chemical reactions and applications. It is commonly used in the synthesis of pharmaceuticals and agrochemicals, as well as in the production of dyes and pigments. Its unique structure and reactivity make it a valuable building block in the field of organic chemistry, with potential uses in drug discovery and materials science.

InChI:InChI=1/C7H3F3N2OS/c8-7(9,10)5-4(3-13)12-1-2-14-6(12)11-5/h1-3H

Upstream product

• 109113-98-6 6-trifluoromethylimidazo<2,1-b>thiazole 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1007874-87-4 6-trifluoromethyl-imidazo[2,1-b]thiazole-5-carboxylic acid 
• 1257653-74-9 (E)-3-(6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one 
• 1257653-76-1 (E)-3-(6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,4-dimethoxyphenyl)prop-2-en-1-one 

Relevant articles and documents

Synthesis of imidazothiazole-chalcone derivatives as anticancer and apoptosis inducing agents

A new class of imidazo[2,1-b]thiazole chalcone derivatives were synthesized and evaluated for their anticancer activity. These chalcone derivatives show promising activity, with logGI50 values ranging from -7.51 to -4.00. The detailed biological aspects of these derivatives toward the MCF-7 cell line were studied. Interestingly, these chalcone derivatives induced G 0/G1-phase cell-cycle arrest, down-regulation of G 1-phase cell-cycle regulatory proteins such as cyclin D1 and cyclin E1, and up-regulation of CDK4. Moreover, these compounds elicit the characteristic features of apoptosis such as enhancement in the levels of p53, p21, and p27, suppression of NF-κB, and up-regulation of caspase-9. One of these chalcone derivatives, 3d, is potentially well suited for detailed biological studies, either alone or in combination with existing therapies. Breaking the cycle: We undertook an extensive examination of the ability of a series of new chalcone derivatives to regulate the cell cycle and to induce apoptosis in various cancer cell lines. Compound 3d is a particularly suitable candidate for further detailed biological investigations, especially in the treatment of breast cancer.

TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES

The invention relates to novel trans-3-aza-bicyclo[3.1.0]hexane derivatives of formula (I), wherein A, B, n and R1 are as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.

2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES

The invention relates to novel 2-aza-bicyclo[3.1.0]hexane derivatives of Formula (I) wherein A, B, n and R1 are as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.